Misonix Exhibits at the Annual Paradigm Medical Management Meeting
FARMINGDALE, N.Y., Oct. 23, 2013
FARMINGDALE, N.Y., Oct. 23, 2013 /PRNewswire/ --Misonix, Inc. (NASDAQ: MSON),
an international surgical device company that designs, manufactures and
markets innovative therapeutic ultrasonic products for spine surgery,
skull-based surgery, neurosurgery, wound debridement, cosmetic surgery,
laparoscopic surgery and other surgical applications, recently participated
the 2013 Paradigm Medical Management Annual Meeting held in Indian Wells, CA
from October 18^th – 20^th, 2013.
Misonix exhibited and presented the newest addition to its wound care line of
devices, the SonicOne^® O.R. Ultrasonic Surgical Debridement System, to
medical directors and wound care program directors of Paradigm managed
hospital programs. The SonicOne O.R. is an innovative surgical device that
allows surgeons to address the challenges chronic wounds present to them, the
patient, and the health-care system. SonicOne O.R. establishes a new standard
in surgical wound bed preparation, an essential first step in the wound
healing process. Use of the SonicOne O.R. system provides controlled tissue
removal, improved healing times, reduced bleeding and a reduction of biofilm.
More than 100 participants attended a presentation by Lee C. Rogers, DPM,
Medical Director of Amputation Prevention Programs for Paradigm Medical
Management, where he featured the clinical benefits of SonicOne O.R. and the
role it plays in the management of patients with wounds. Dr. Rogers commented,
"This device is a no-brainer for our hospital programs. It debrides better and
more selectively than existing technology and it's more cost effective."
Additionally, Diane Boone, Chief Executive officer of Paradigm Medical
Management offered, "Our job as a management company is to help develop
pathways to improve outcomes for healing wounds while improving the bottom
line for the hospital. SonicOne does both and we're proud to work with Misonix
to offer our hospital programs this advanced technology."
Michael A. McManus, Jr., President and Chief Executive Officer of Misonix
comments, "We are very pleased to see that our SonicOne O.R. technology is
quickly gaining recognition by hospital systems and medical management systems
such as Paradigm Medical Management as an important part of their treatment
algorithm in their wound care programs. This level of interest speaks not only
to the clinical importance of our technology but to the economics of treating
these patients as well."
About Paradigm Medical Management
Paradigm Medical Management (PMM) is dedicated to the development,
implementation, and management of hospital-based outpatient wound healing,
amputation prevention and hyperbaric medicine programs. Paradigm is able to
offer physicians and their patients access to the latest in technological
innovations and best practice models.
With unique experience and expertise in managed care, including capitated
environments and shared risk arrangements, Paradigm has developed a proven,
successful strategy to provide managed care enrollees access to wound
management and hyperbaric clinics within Paradigm-affiliated hospitals.
Paradigm is expanding its network of amputation prevention centers under the
umbrella of the Amputation Prevention Centers of America®. More information
can be found on PMM's website at www.pmmhealthcare.com.
Misonix, Inc. designs, develops, manufactures and markets therapeutic
ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the
basis for several innovative medical technologies. Addressing a combined
market estimated to be in excess of $3 billion annually; Misonix's proprietary
ultrasonic medical devices are used for wound debridement, cosmetic surgery,
neurosurgery, laparoscopic surgery, and other surgical and medical
applications. Additional information is available on the Company's Web site at
Safe Harbor Statement
With the exception of historical information contained in this press release,
content herein may contain "forward looking statements" that are made pursuant
to the Safe Harbor Provisions of the Private Securities Litigation Reform Act
of 1995. These statements are based on management's current expectations and
are subject to uncertainty and changes in circumstances. Investors are
cautioned that forward-looking statements involve risks and uncertainties that
could cause actual results to differ materially from the statements made.
These factors include general economic conditions, delays and risks associated
with the performance of contracts, risks associated with international sales
and currency fluctuations, uncertainties as a result of research and
development, acceptable results from clinical studies, including publication
of results and patient/procedure data with varying levels of statistical
relevancy, risks involved in introducing and marketing new products, potential
acquisitions, consumer and industry acceptance, litigation and/or court
proceedings, including the timing and monetary requirements of such
activities, the timing of finding strategic partners and implementing such
relationships, regulatory risks including approval of pending and/or
contemplated 510(k) filings, the ability to achieve and maintain profitability
in the Company's business lines, and other factors discussed in the Company's
Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and
Current Reports on Form 8-K. The Company disclaims any obligation to update
its forward-looking relationships.
Misonix Contact: Investor Contact:
Richard Zaremba Joe Diaz
631-694-9555 Lytham Partners
SOURCE Misonix, Inc.
Press spacebar to pause and continue. Press esc to stop.